Company news

Alterity Therapeutics Ltd. news in 2026

Alterity Therapeutics Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Proposed issue of securities - ATH

October 23, 2026

Notification regarding unquoted securities - ATH

October 22, 2026

Notification regarding unquoted securities - ATH

October 22, 2026

Notice of Annual General Meeting/Proxy Form

October 21, 2026

Changes to Managing Director Terms of Employment

October 21, 2026

Alterity to Present at the Craig-Hallum Biotech Conference

October 18, 2026

Alterity to Present at Canaccord Drug and Device Conference

October 8, 2026

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

October 5, 2026

Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA

October 4, 2026

Date of AGM and Closing Date for Director Nominations

September 24, 2026

Corporate Presentation September 2026

September 22, 2026

Alterity Therapeutics to Present at ASX SMIDcaps Conference

September 17, 2026

Application for quotation of securities - ATH

September 15, 2026

Cleansing Notice Under Section 708A

September 7, 2026

Application for quotation of securities - ATH

September 7, 2026

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

September 3, 2026

Alterity to Present at Cantor Global Healthcare Conference

September 2, 2026

Change of Director's Interest Notice - Stamler

September 1, 2026

Change of Director's Interest Notice - Marks

September 1, 2026

Application for quotation of securities - ATH

September 1, 2026

Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC

August 30, 2026

$4.2M Options Underwriting Agreement Executed

August 30, 2026

Application for quotation of securities - ATH

August 28, 2026

Appendix 4E and 2026 Annual Report

August 28, 2026

Corporate Governance Statement

August 28, 2026

Appendix 4G

August 28, 2026

Application for quotation of securities - ATH

August 21, 2026

Disclosure Under Takeovers Panel GN 20

August 17, 2026

Application for quotation of securities - ATH

August 14, 2026

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

August 12, 2026

Granted New U.S. Composition of Matter Patent for ATH434

August 11, 2026

Application for quotation of securities - ATH

August 10, 2026

Alterity to Present at Canaccord Genuity Growth Conference

August 5, 2026

Application for quotation of securities - ATH

August 3, 2026

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

July 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 29, 2026

Upcoming Expiry of ATHO Listed Options

July 28, 2026

Application for quotation of securities - ATH

July 27, 2026

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

July 21, 2026

ATH Receives A$3.98m R&D Tax Incentive

July 9, 2026

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

July 7, 2026

FDA Meeting Minutes Confirm Registrational Path for ATH434

July 6, 2026

Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

May 18, 2026

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

May 11, 2026

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

May 10, 2026

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

May 7, 2026

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

April 30, 2026

Notice of General Meeting/Proxy Form

April 29, 2026

Older news releases →

Decks in 2026